Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Study on the Prevention of Recidivism and the Consequences of Sexual Violence Suffered by Female Asylum Seekers in France

NCT07477314 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-04-29
Last updated
2026-10-13

Condition(s) studied

Sexual ViolenceRefugee HealthPhysical HealthMental HealthQuality of LifeAccess to Recommended Healthcare

Investigational drug(s) / intervention(s)

care coordinatora trained health mediatorAccess to care in the usual careAccess to care in the Coordinated care modelCoordinationCoordinationDetection of sexual violenceDetection of sexual violenceMedical follow-upMedical follow-upTraining of professionalsTraining of professionals

care coordinator: The care coordinator ensures organisation of the care pathway, liaison between professionals, and longitudinal follow-up in collaboration with a general practitioner.

a trained health mediator: The health mediator facilitates communication, supports participants in navigating healthcare and social systems, and helps reduce linguistic, cultural, and administrative barriers.

Access to care in the usual care: Depends on asylum seekers' individual initiatives

Access to care in the Coordinated care model: Systematically initiated from registration at the first reception centre (PADA)

Coordination: Fragmented, dependent on local structures

Coordination: Provided by a coordinating care professionnal

Detection of sexual violence: Based on victims' self-reporting

Detection of sexual violence: Proactive approach with health mediation and training of healthcare professionals

Medical follow-up: Irregular, often interrupted due to precarious living conditions

Medical follow-up: Progressive integration into mainstream healthcare services

Training of professionals: Variable, not standardized

Training of professionals: Specialized and systematic training on sexual violence

Study summary

Women seeking asylum (WSA) are overexposed to sexual violence (SV) in their countries of origin, along migration routes, and within host countries. This overexposure does not cease upon arrival in host countries; on the contrary, the first months following arrival are characterised by heightened vulnerability, with an increased incidence of sexual violence, particularly among women with a prior history of victimisation.

Sexual violence has major consequences on physical health, mental health, quality of life, and healthcare utilisation, and generates substantial individual and societal costs. International organisations, including the United Nations High Commissioner for Refugees, have identified the prevention of sexual violence and the improvement of care for survivors as public health priorities.

Previous work suggests that addressing sexual violence within primary care, when embedded in a comprehensive, culturally informed, and coordinated approach integrating medical, psychological, social, and medico-legal dimensions, may contribute to preventing the occurrence or recurrence of sexual violence in host countries. However, no comparative study has yet evaluated the effectiveness of such a coordinated model of care on the prevention of sexual violence among women seeking asylum, nor assessed its efficiency or transferability.

The primary objective of this study is to evaluate the effectiveness of a coordinated, transcultural, multidisciplinary outpatient care model on the prevention of sexual violence occurring in host European countries among women seeking asylum.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Woman seeking asylum in France * Asylum application registered less than 3 months before inclusion. * Self-identified female gender. * Age ≥ 18 years. * Received study information and provided informed consent to participate Exclusion Criteria: * Re-examination of a previous asylum application. * Major cognitive impairment (e.g. dementia or intellectual disability) preventing reliable collection of study outcomes.

Primary outcome measure(s)

  • Occurrence of sexual violence within 12 months after inclusion — 12 months after inclusion
    The primary outcome is the occurrence of sexual violence during the first 12 months following inclusion. Sexual violence is defined as the occurrence of at least one of the following events: rape, attempted rape, sexual assault, or sexual exhibition, as assessed through structured interviews administered at follow-up visits.

Trial sites (6)

FacilityCityRegionStatus
Maison de Santé de Saint André Bordeaux France Recruiting
MSP soins premiers Villeurbanne Est Lyon France Not Yet Recruiting
Maison de Santé PEYSSONEL Marseille France Recruiting
Maison de Santé Butte Sainte Anne Nantes France Recruiting
MSP Mathagon Paris France Not Yet Recruiting
Maison de santé Bonnefoy Périole Roseraie Toulouse France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07477314 on ClinicalTrials.gov ↗ ← All trials in France